Accuray up after positive follow-up data on cancer treatment system

Accuray

14/09/2021 14:13

** Medical device maker's shares  ARAY.O  up 3.5% at $3.8
    ** ARAY announced positive data from a two-year follow-up
study of CyberKnife, its FDA-approved robotic platform for
radiotherapy on various types of cancers
    ** Co says prostate cancer patients who were treated by
CyberKnife experienced side effects in their bladder half as
much as patients who were treated with conventional radiotherapy
devices
    ** Follow-up study was conducted at 37 sites in the UK,
Canada and Ireland
    ** Stock down ~12% this year, as of Monday's close

 (Reporting by Ruhi Soni in Bengaluru;)
 ((Ruhi.Soni@thomsonreuters.com;))